Can’t Win Them All: Two Merck Oncology Trials Fail

Stalwarts Lynparza And Keytruda Miss Their Mark

 
• By Alaric DeArment

The company stopped a study of Lynparza in colorectal cancer for futility and announced a study of Keytruda/chemoradiation in head-and-neck cancer didn’t meet its primary endpoint.

Merck posted two back-to-back trial failures, but there are further opportunities ahead • Source: Shutterstock

More from Anticancer

More from Therapy Areas